Takeda takes a chance on ImmunoGen's ADC technology
This article was originally published in Scrip
Executive Summary
ImmunoGen has seen a partial recovery of its share price on news that Takeda Pharmaceutical has licensed exclusive rights to its antibody-drug conjugated (ADC) technology to develop anticancer therapeutics to two undisclosed targets. In pre-market trading ImmunoGen's shares rose 17% to $8.71.